Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis
OBJECTIVE—Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies. APPROACH AND RESULTS—Citrated human blood was supplemented with...
Gespeichert in:
Veröffentlicht in: | Arteriosclerosis, thrombosis, and vascular biology thrombosis, and vascular biology, 2018-11, Vol.38 (11), p.2626-2637 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2637 |
---|---|
container_issue | 11 |
container_start_page | 2626 |
container_title | Arteriosclerosis, thrombosis, and vascular biology |
container_volume | 38 |
creator | Loyau, Stéphane Ho-Tin-Noé, Benoit Bourrienne, Marie-Charlotte Boulaftali, Yacine Jandrot-Perrus, Martine |
description | OBJECTIVE—Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies.
APPROACH AND RESULTS—Citrated human blood was supplemented with 3,3′-dihexyloxacarbocyanine iodide and Alexa Fluor 647 fibrinogen conjugate, recalcified, and perfused for 3 to 4 minutes at venous or arterial wall shear rate in microfluidic flow chambers coated with collagen and tissue factor to generate nonocclusive fluorescent thrombi. A second perfusion was performed for 10 minutes with rhodamine-6G-labeled citrated whole blood, supplemented or not with r-tPA (recombinant tissue-type plasminogen activator), fluorescein isothiocyanate-conjugated r-tPA, and Alexa Fluor 568 plasminogen conjugate. Plasminogen and r-tPA bound to preformed thrombi and r-tPA caused a concentration-dependent decrease in thrombus fibrin content (up to 50% reduction at 15 µg/mL r-tPA) as assessed by fluorescence microscopy. Fibrinolysis was confirmed by measurement of D-dimers in the output flow. Remarkably, despite ongoing fibrinolysis, new platelets continued to be recruited to the thrombus under lysis. Under the arterial condition, combining r-tPA with hirudin enhanced fibrinolysis but did not prevent the recruitment of new platelets, which was, however, prevented by antiplatelet agents (ticagrelor or the GPVI [glycoprotein VI]-blocking antigen-binding fragment 9O12).
CONCLUSIONS—Our microfluidic thrombolysis model is suitable for studying thrombolysis and testing the efficacy of drugs used in combination with r-tPA. Real-time analysis of fibrin and platelets during r-tPA-mediated fibrinolysis at arterial or venous flow conditions showed that platelets continue to accumulate during fibrinolysis. Such platelet accumulation may impair r-tPA-mediated recanalization. |
doi_str_mv | 10.1161/ATVBAHA.118.311178 |
format | Article |
fullrecord | <record><control><sourceid>wolterskluwer_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1161_ATVBAHA_118_311178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10.1161/ATVBAHA.118.311178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2458-ad434cb9ff5543f26d959c04e55c6a2f3605f561f8a58c5f1b84330077c743e3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRSMEEqXwA6y8hEWKHT-SsAtVSyu1oouIbeQ4dmtw48p2qPojfC_pY81q5t6ZOyOdKHpEcIQQQy9F-flWzIpeZCOMEEqzq2iAaEJiwjC77nuY5jFlJLmN7rz_ghCSJIGD6HephbPKdLrRAixtI41u18AqUG6c3dbWHLz2r2CilBTh6Bdt0DvDgzQyAN42J0NYvu4MbwMo1rINHtgWhFUBnkrtfSfj8rCTYGW43-rW9hugEEH_8GDdczxvm07IBkx17frp6eF9dKO48fLhUodROZ2U41m8-Hifj4tFLBJCs5g3BBNR50pRSrBKWJPTXEAiKRWMJwozSBVlSGWcZoIqVGcEYwjTVKQESzyMkvPZnoH3Tqpq5_SWu0OFYHUEW13A9iKrzmD7EDuH9tYE6fy36fbSVRvJTdj8F_wDk9V_-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis</title><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Loyau, Stéphane ; Ho-Tin-Noé, Benoit ; Bourrienne, Marie-Charlotte ; Boulaftali, Yacine ; Jandrot-Perrus, Martine</creator><creatorcontrib>Loyau, Stéphane ; Ho-Tin-Noé, Benoit ; Bourrienne, Marie-Charlotte ; Boulaftali, Yacine ; Jandrot-Perrus, Martine</creatorcontrib><description>OBJECTIVE—Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies.
APPROACH AND RESULTS—Citrated human blood was supplemented with 3,3′-dihexyloxacarbocyanine iodide and Alexa Fluor 647 fibrinogen conjugate, recalcified, and perfused for 3 to 4 minutes at venous or arterial wall shear rate in microfluidic flow chambers coated with collagen and tissue factor to generate nonocclusive fluorescent thrombi. A second perfusion was performed for 10 minutes with rhodamine-6G-labeled citrated whole blood, supplemented or not with r-tPA (recombinant tissue-type plasminogen activator), fluorescein isothiocyanate-conjugated r-tPA, and Alexa Fluor 568 plasminogen conjugate. Plasminogen and r-tPA bound to preformed thrombi and r-tPA caused a concentration-dependent decrease in thrombus fibrin content (up to 50% reduction at 15 µg/mL r-tPA) as assessed by fluorescence microscopy. Fibrinolysis was confirmed by measurement of D-dimers in the output flow. Remarkably, despite ongoing fibrinolysis, new platelets continued to be recruited to the thrombus under lysis. Under the arterial condition, combining r-tPA with hirudin enhanced fibrinolysis but did not prevent the recruitment of new platelets, which was, however, prevented by antiplatelet agents (ticagrelor or the GPVI [glycoprotein VI]-blocking antigen-binding fragment 9O12).
CONCLUSIONS—Our microfluidic thrombolysis model is suitable for studying thrombolysis and testing the efficacy of drugs used in combination with r-tPA. Real-time analysis of fibrin and platelets during r-tPA-mediated fibrinolysis at arterial or venous flow conditions showed that platelets continue to accumulate during fibrinolysis. Such platelet accumulation may impair r-tPA-mediated recanalization.</description><identifier>ISSN: 1079-5642</identifier><identifier>EISSN: 1524-4636</identifier><identifier>DOI: 10.1161/ATVBAHA.118.311178</identifier><language>eng</language><publisher>American Heart Association, Inc</publisher><ispartof>Arteriosclerosis, thrombosis, and vascular biology, 2018-11, Vol.38 (11), p.2626-2637</ispartof><rights>2018 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2458-ad434cb9ff5543f26d959c04e55c6a2f3605f561f8a58c5f1b84330077c743e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Loyau, Stéphane</creatorcontrib><creatorcontrib>Ho-Tin-Noé, Benoit</creatorcontrib><creatorcontrib>Bourrienne, Marie-Charlotte</creatorcontrib><creatorcontrib>Boulaftali, Yacine</creatorcontrib><creatorcontrib>Jandrot-Perrus, Martine</creatorcontrib><title>Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis</title><title>Arteriosclerosis, thrombosis, and vascular biology</title><description>OBJECTIVE—Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies.
APPROACH AND RESULTS—Citrated human blood was supplemented with 3,3′-dihexyloxacarbocyanine iodide and Alexa Fluor 647 fibrinogen conjugate, recalcified, and perfused for 3 to 4 minutes at venous or arterial wall shear rate in microfluidic flow chambers coated with collagen and tissue factor to generate nonocclusive fluorescent thrombi. A second perfusion was performed for 10 minutes with rhodamine-6G-labeled citrated whole blood, supplemented or not with r-tPA (recombinant tissue-type plasminogen activator), fluorescein isothiocyanate-conjugated r-tPA, and Alexa Fluor 568 plasminogen conjugate. Plasminogen and r-tPA bound to preformed thrombi and r-tPA caused a concentration-dependent decrease in thrombus fibrin content (up to 50% reduction at 15 µg/mL r-tPA) as assessed by fluorescence microscopy. Fibrinolysis was confirmed by measurement of D-dimers in the output flow. Remarkably, despite ongoing fibrinolysis, new platelets continued to be recruited to the thrombus under lysis. Under the arterial condition, combining r-tPA with hirudin enhanced fibrinolysis but did not prevent the recruitment of new platelets, which was, however, prevented by antiplatelet agents (ticagrelor or the GPVI [glycoprotein VI]-blocking antigen-binding fragment 9O12).
CONCLUSIONS—Our microfluidic thrombolysis model is suitable for studying thrombolysis and testing the efficacy of drugs used in combination with r-tPA. Real-time analysis of fibrin and platelets during r-tPA-mediated fibrinolysis at arterial or venous flow conditions showed that platelets continue to accumulate during fibrinolysis. Such platelet accumulation may impair r-tPA-mediated recanalization.</description><issn>1079-5642</issn><issn>1524-4636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRSMEEqXwA6y8hEWKHT-SsAtVSyu1oouIbeQ4dmtw48p2qPojfC_pY81q5t6ZOyOdKHpEcIQQQy9F-flWzIpeZCOMEEqzq2iAaEJiwjC77nuY5jFlJLmN7rz_ghCSJIGD6HephbPKdLrRAixtI41u18AqUG6c3dbWHLz2r2CilBTh6Bdt0DvDgzQyAN42J0NYvu4MbwMo1rINHtgWhFUBnkrtfSfj8rCTYGW43-rW9hugEEH_8GDdczxvm07IBkx17frp6eF9dKO48fLhUodROZ2U41m8-Hifj4tFLBJCs5g3BBNR50pRSrBKWJPTXEAiKRWMJwozSBVlSGWcZoIqVGcEYwjTVKQESzyMkvPZnoH3Tqpq5_SWu0OFYHUEW13A9iKrzmD7EDuH9tYE6fy36fbSVRvJTdj8F_wDk9V_-w</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Loyau, Stéphane</creator><creator>Ho-Tin-Noé, Benoit</creator><creator>Bourrienne, Marie-Charlotte</creator><creator>Boulaftali, Yacine</creator><creator>Jandrot-Perrus, Martine</creator><general>American Heart Association, Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20181101</creationdate><title>Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis</title><author>Loyau, Stéphane ; Ho-Tin-Noé, Benoit ; Bourrienne, Marie-Charlotte ; Boulaftali, Yacine ; Jandrot-Perrus, Martine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2458-ad434cb9ff5543f26d959c04e55c6a2f3605f561f8a58c5f1b84330077c743e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loyau, Stéphane</creatorcontrib><creatorcontrib>Ho-Tin-Noé, Benoit</creatorcontrib><creatorcontrib>Bourrienne, Marie-Charlotte</creatorcontrib><creatorcontrib>Boulaftali, Yacine</creatorcontrib><creatorcontrib>Jandrot-Perrus, Martine</creatorcontrib><collection>CrossRef</collection><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loyau, Stéphane</au><au>Ho-Tin-Noé, Benoit</au><au>Bourrienne, Marie-Charlotte</au><au>Boulaftali, Yacine</au><au>Jandrot-Perrus, Martine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis</atitle><jtitle>Arteriosclerosis, thrombosis, and vascular biology</jtitle><date>2018-11-01</date><risdate>2018</risdate><volume>38</volume><issue>11</issue><spage>2626</spage><epage>2637</epage><pages>2626-2637</pages><issn>1079-5642</issn><eissn>1524-4636</eissn><abstract>OBJECTIVE—Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies.
APPROACH AND RESULTS—Citrated human blood was supplemented with 3,3′-dihexyloxacarbocyanine iodide and Alexa Fluor 647 fibrinogen conjugate, recalcified, and perfused for 3 to 4 minutes at venous or arterial wall shear rate in microfluidic flow chambers coated with collagen and tissue factor to generate nonocclusive fluorescent thrombi. A second perfusion was performed for 10 minutes with rhodamine-6G-labeled citrated whole blood, supplemented or not with r-tPA (recombinant tissue-type plasminogen activator), fluorescein isothiocyanate-conjugated r-tPA, and Alexa Fluor 568 plasminogen conjugate. Plasminogen and r-tPA bound to preformed thrombi and r-tPA caused a concentration-dependent decrease in thrombus fibrin content (up to 50% reduction at 15 µg/mL r-tPA) as assessed by fluorescence microscopy. Fibrinolysis was confirmed by measurement of D-dimers in the output flow. Remarkably, despite ongoing fibrinolysis, new platelets continued to be recruited to the thrombus under lysis. Under the arterial condition, combining r-tPA with hirudin enhanced fibrinolysis but did not prevent the recruitment of new platelets, which was, however, prevented by antiplatelet agents (ticagrelor or the GPVI [glycoprotein VI]-blocking antigen-binding fragment 9O12).
CONCLUSIONS—Our microfluidic thrombolysis model is suitable for studying thrombolysis and testing the efficacy of drugs used in combination with r-tPA. Real-time analysis of fibrin and platelets during r-tPA-mediated fibrinolysis at arterial or venous flow conditions showed that platelets continue to accumulate during fibrinolysis. Such platelet accumulation may impair r-tPA-mediated recanalization.</abstract><pub>American Heart Association, Inc</pub><doi>10.1161/ATVBAHA.118.311178</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-5642 |
ispartof | Arteriosclerosis, thrombosis, and vascular biology, 2018-11, Vol.38 (11), p.2626-2637 |
issn | 1079-5642 1524-4636 |
language | eng |
recordid | cdi_crossref_primary_10_1161_ATVBAHA_118_311178 |
source | Journals@Ovid Complete; Alma/SFX Local Collection |
title | Microfluidic Modeling of Thrombolysis: Effect of Antiplatelet and Anticoagulant Agents on tPA (Tissue-Type Plasminogen Activator)-Induced Fibrinolysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A39%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microfluidic%20Modeling%20of%20Thrombolysis:%20Effect%20of%20Antiplatelet%20and%20Anticoagulant%20Agents%20on%20tPA%20(Tissue-Type%20Plasminogen%20Activator)-Induced%20Fibrinolysis&rft.jtitle=Arteriosclerosis,%20thrombosis,%20and%20vascular%20biology&rft.au=Loyau,%20St%C3%A9phane&rft.date=2018-11-01&rft.volume=38&rft.issue=11&rft.spage=2626&rft.epage=2637&rft.pages=2626-2637&rft.issn=1079-5642&rft.eissn=1524-4636&rft_id=info:doi/10.1161/ATVBAHA.118.311178&rft_dat=%3Cwolterskluwer_cross%3E10.1161/ATVBAHA.118.311178%3C/wolterskluwer_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |